HY-022619
/ Hefei Yigong Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
Phase I clinical study of safety, tolerability, and pharmacokinetics/pharmacodynamics of HY-022619 for injection in a randomized, double-blind, placebo/positive-controlled, dose-increasing single administration in healthy Chinese adult subjects
(ChiCTR)
- P1 | N=30 | Not yet recruiting | Sponsor: The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University
New P1 trial • Acute Coronary Syndrome • Cardiovascular
1 to 1
Of
1
Go to page
1